Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis opticaÉdouard Januel, Pierre Labauge, S. Beltran et al.|Multiple Sclerosis Journal|2021Cited by 18
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Jeannette Lechner‐Scott et al.|CNS Drugs|2021Cited by 12
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisMathilde Lefort, F. Grand’Maison, Jean‐Philippe Camdessanché et al.|BMC Medical Research Methodology|2022Cited by 6